Drug Trial Radar · NCT00519753
Success of Transitioning Uncontrolled Glaucoma Patients From Prior Mono or Adjunctive Therapy to DuoTrav
Last checked: Nov 20, 2026Latest source record: Nov 18, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
522
Actual
Start
Aug 2007
Primary completion
Dec 2008
Study completion Dec 2008
Sponsor
- Lead sponsor
- Alcon ResearchIndustry
- Sponsor type
- Industry
- First posted
- Aug 23, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of transitioning uncontrolled glaucoma patients to DuoTrav from other mono or adjunctive therapies.
Conditions
- Glaucoma
Interventions
Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav)Drug
One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in intraocular pressure at 12 weeks from travoprost prior therapy (baseline)Time frame: Baseline and 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mainz
Mainz, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.